Company / Gross Profit
Idexx Laboratories Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$2.7B
FY2025
5-year range
$1.9B / $2.7B
FY2021-FY2025
Trend
+11.8%
vs FY2024
Sector context
#21 of 95
Health Care
What the data says
Idexx Laboratories's gross profit of $2.7B is higher than 78% of companies in the Health Care sector (FY2025). Gross Profit has increased for 9 consecutive years, from $975M in FY2016 to $2.7B in FY2025.
Based on SEC 10-K filings.
$2.7B in FY2025 with a 5-year CAGR of +11.1%. Top quartile in the Health Care sector.
Improved from $2.2B to $2.7B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +9.9%
- 5-Year CAGR
- +11.1%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 95This company $2.7B Sector average $1.9B
▼
+41.9% above sector average
Key checks
Key Insights
- Idexx Laboratories's gross profit has grown for 9 consecutive years.
- 5-year CAGR of +11.1%, indicating consistent growth.
- In FY2025, gross profit increased 11.8% year-over-year.
- Ranks #21 out of 95 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.7B | +11.8% |
| FY2024 | $2.4B | +8.6% |
| FY2023 | $2.2B | +9.3% |
| FY2022 | $2.0B | +6.1% |
| FY2021 | $1.9B | +20.3% |
| FY2020 | $1.6B | +15.0% |
| FY2019 | $1.4B | +10.0% |
| FY2018 | $1.2B | +13.1% |
| FY2017 | $1.1B | +12.5% |
| FY2016 | $975.4M | +9.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026